These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28708736)

  • 1. Mifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic Depression.
    Block T; Petrides G; Kushner H; Kalin N; Belanoff J; Schatzberg A
    J Clin Psychopharmacol; 2017 Oct; 37(5):505-511. PubMed ID: 28708736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and biological effects of mifepristone treatment for psychotic depression.
    Flores BH; Kenna H; Keller J; Solvason HB; Schatzberg AF
    Neuropsychopharmacology; 2006 Mar; 31(3):628-36. PubMed ID: 16160710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction.
    Blasey CM; Debattista C; Roe R; Block T; Belanoff JK
    Contemp Clin Trials; 2009 Jul; 30(4):284-8. PubMed ID: 19318138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Analysis of Mifepristone for Psychotic Depression: Plasma Levels Associated With Clinical Response.
    Block TS; Kushner H; Kalin N; Nelson C; Belanoff J; Schatzberg A
    Biol Psychiatry; 2018 Jul; 84(1):46-54. PubMed ID: 29523415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression.
    Simpson GM; El Sheshai A; Loza N; Kingsbury SJ; Fayek M; Rady A; Fawzy W
    J Clin Psychiatry; 2005 May; 66(5):598-602. PubMed ID: 15889946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation.
    Bertagna X; Escourolle H; Pinquier JL; Coste J; Raux-Demay MC; Perles P; Silvestre L; Luton JP; Strauch G
    J Clin Endocrinol Metab; 1994 Feb; 78(2):375-80. PubMed ID: 8106625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression.
    DeBattista C; Belanoff J; Glass S; Khan A; Horne RL; Blasey C; Carpenter LL; Alva G
    Biol Psychiatry; 2006 Dec; 60(12):1343-9. PubMed ID: 16889757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid reversal of psychotic depression using mifepristone.
    Belanoff JK; Flores BH; Kalezhan M; Sund B; Schatzberg AF
    J Clin Psychopharmacol; 2001 Oct; 21(5):516-21. PubMed ID: 11593077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia.
    Gallagher P; Watson S; Elizabeth Dye C; Young AH; Nicol Ferrier I
    J Psychiatr Res; 2008 Oct; 42(12):1037-41. PubMed ID: 18255098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
    Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
    Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of mifepristone for the treatment of psychotic depression.
    Blasey CM; Block TS; Belanoff JK; Roe RL
    J Clin Psychopharmacol; 2011 Aug; 31(4):436-40. PubMed ID: 21694614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder.
    Young AH; Gallagher P; Watson S; Del-Estal D; Owen BM; Ferrier IN
    Neuropsychopharmacology; 2004 Aug; 29(8):1538-45. PubMed ID: 15127079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open label trial of C-1073 (mifepristone) for psychotic major depression.
    Belanoff JK; Rothschild AJ; Cassidy F; DeBattista C; Baulieu EE; Schold C; Schatzberg AF
    Biol Psychiatry; 2002 Sep; 52(5):386-92. PubMed ID: 12242054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the glucocorticoid antagonist RU 486 on pituitary-adrenal function in patients with anorexia nervosa and healthy volunteers: enhancement of plasma ACTH and cortisol secretion in underweight patients.
    Kling MA; Demitrack MA; Whitfield HJ; Kalogeras KT; Listwak SJ; DeBellis MD; Chrousos GP; Gold PW; Brandt HA
    Neuroendocrinology; 1993 Jun; 57(6):1082-91. PubMed ID: 8232766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is mifepristone useful in psychotic depression?
    Carroll BJ; Rubin RT
    Neuropsychopharmacology; 2006 Dec; 31(12):2793-4; author reply 2795-7. PubMed ID: 17109015
    [No Abstract]   [Full Text] [Related]  

  • 20. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
    Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
    J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.